Avid Bioservices, Inc. revised revenue guidance for the full fiscal year 2024. The company is adjusting revenue guidance for full fiscal year 2024 to $137 million to $147 million, previously $145 million and $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.77 USD | +2.52% |
|
+32.21% | +50.31% |
Jul. 02 | Avid Bioservices Fiscal Q4 Loss Widens, Revenue Increases; Fiscal 2025 Revenue Outlook Set | MT |
Jul. 02 | Transcript : Avid Bioservices, Inc., Q4 2024 Earnings Call, Jul 02, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.31% | 606M | |
+7.46% | 100B | |
+11.97% | 42.34B | |
-11.76% | 32.76B | |
+79.34% | 29.46B | |
-12.20% | 16.31B | |
+4.00% | 14.39B | |
-1.90% | 12.23B | |
+178.17% | 10.47B | |
+1.80% | 8.97B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024